Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Initial Management Approach For Localized/locally Advanced Disease Is Critical To Guide Metastatic Castration-resistant Prostate Cancer Care

Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care

Vincenza Conteduca1, Piergiorgio Di Tullio2, Rossana Allamprese2,3

  • 1Unit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti, 71122, Foggia, Italy. vincenza.conteduca@unifg.it.

Prostate Cancer and Prostatic Diseases
|February 12, 2024

Related Experiment Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K
Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

7.8K

View abstract on PubMed

Summary
This summary is machine-generated.

Longer duration of androgen-deprivation therapy (ADT) for hormone-sensitive prostate cancer (HSPC) is linked to better survival in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with androgen-receptor-signaling inhibitors (ARSI). This suggests initial prostate cancer management impacts long-term outcomes.

Related Experiment Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K
Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

7.8K

Area of Science:

  • Oncology
  • Urology
  • Clinical Medicine

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) has limited personalized treatment factors.
  • Androgen-deprivation therapy (ADT) is a standard treatment for hormone-sensitive prostate cancer (HSPC).

Purpose of the Study:

  • To investigate the prognostic value of ADT duration in HSPC for patients receiving androgen-receptor-signaling inhibitors (ARSI) for mCRPC.
  • To identify clinical factors for personalizing mCRPC treatment.

Main Methods:

  • A multicenter cohort of 919 mCRPC patients treated with ARSI was analyzed.
  • Patients were classified based on initial disease burden and ADT duration (short-term <24 months vs. long-term ≥24 months).
  • Outcomes including overall survival (OS) and progression-free survival (PFS) were assessed using multivariate analysis.

Main Results:

  • Short-term ADT (<24 months) in primary progressive mCRPC was associated with a nearly double risk of death compared to long-term ADT (≥24 months).
  • Multivariate analysis confirmed shorter ADT duration was linked to worse OS and PFS.
  • Longer time to castration resistance in de novo mHSPC patients correlated with better OS and PFS.

Conclusions:

  • ADT duration for HSPC is significantly associated with survival outcomes in mCRPC patients treated with ARSI.
  • Initial prostate cancer management may influence prognostication in mCRPC.
  • Prospective trials are needed to confirm these findings and guide treatment strategies.